Altimmune Inc (ALT)
7.39
-0.50
(-6.34%)
USD |
NASDAQ |
May 23, 16:00
7.51
+0.12
(+1.62%)
Pre-Market: 08:23
Altimmune Accounts Payable (Quarterly): 3.76M for March 31, 2024
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 3.76M |
December 31, 2023 | 2.07M |
September 30, 2023 | 3.046M |
June 30, 2023 | 4.035M |
March 31, 2023 | 5.238M |
December 31, 2022 | 4.804M |
September 30, 2022 | 1.419M |
June 30, 2022 | 2.872M |
March 31, 2022 | 2.205M |
December 31, 2021 | 2.034M |
September 30, 2021 | 0.0061M |
June 30, 2021 | 1.421M |
March 31, 2021 | 0.4182M |
December 31, 2020 | 0.6123M |
September 30, 2020 | 0.8749M |
June 30, 2020 | 0.1952M |
March 31, 2020 | 0.9296M |
December 31, 2019 | 0.0182M |
September 30, 2019 | 0.0499M |
June 30, 2019 | 0.2701M |
March 31, 2019 | 0.0148M |
December 31, 2018 | 0.3729M |
September 30, 2018 | 0.1507M |
June 30, 2018 | 0.2452M |
March 31, 2018 | 0.5132M |
Date | Value |
---|---|
December 31, 2017 | 0.1291M |
September 30, 2017 | 0.4951M |
June 30, 2017 | 1.131M |
March 31, 2017 | 0.8395M |
December 31, 2016 | 2.005M |
September 30, 2016 | 0.6145M |
June 30, 2016 | 0.7111M |
March 31, 2016 | 0.1664M |
December 31, 2015 | 0.5211M |
September 30, 2015 | 0.3062M |
June 30, 2015 | 0.2085M |
March 31, 2015 | 0.537M |
December 31, 2014 | 0.3914M |
September 30, 2014 | 0.282M |
June 30, 2014 | 0.4374M |
March 31, 2014 | 0.4718M |
December 31, 2013 | 1.128M |
September 30, 2013 | 1.159M |
June 30, 2013 | 2.992M |
March 31, 2013 | 1.290M |
December 31, 2012 | 1.697M |
September 30, 2012 | 1.847M |
June 30, 2012 | 2.063M |
March 31, 2012 | 1.410M |
December 31, 2011 | 1.446M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
0.0061M
Minimum
Sep 2021
5.238M
Maximum
Mar 2023
1.814M
Average
1.420M
Median
Accounts Payable (Quarterly) Benchmarks
Eli Lilly and Co | 2.474B |
Amgen Inc | 1.628B |
Pfizer Inc | 5.591B |
Viking Therapeutics Inc | 5.225M |
GlycoMimetics Inc | 0.7555M |